Bildkälla: Stockfoto

Medivir: Q1’21, Solid Report - Redeye

Redeye believes the CEO's resignation has shrouded underlying progress for Medivir lately. Near-term updates regarding lead candidate MIV-818 could trigger increased interest in the shares, however.

Redeye believes the CEO's resignation has shrouded underlying progress for Medivir lately. Near-term updates regarding lead candidate MIV-818 could trigger increased interest in the shares, however.
Börsvärldens nyhetsbrev
ANNONSER